Irfan Perente

Irfan Perente

Auto-generated profile, based on publicly available information

Irfan Perente

Univ Hosp Alexandroupolis, Dept Ophthalmol, Alexandroupolis, Greece

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

1 January 2017 in Korean Journal of Ophthalmology
Verified
Journal Article
Open access
PDF file
AOAbdullah Ozkaya
Abdullah Ozkaya
ZAZeynep Alkin
Zeynep Alkin
MTMesut Togac
Mesut Togac
SASibel AHMET
Sibel AHMET
IPIrfan Perente
Irfan Perente
MTMuhittin Taskapili
Muhittin Taskapili
Ozkaya A, et al. Korean J Ophthalmol. 2017 Oct;31(5):424-430. https://doi.org/10.3341/kjo.2016.0125

1 October 2018 in Turkish Journal of Ophthalmology
Verified
Journal Article
Open access
AOAbdullah Ozkaya
Abdullah Ozkaya
LKLevent Karabaş
Levent Karabaş
CACengiz Alagöz
Cengiz Alagöz
ZAZeynep Alkın
Zeynep Alkın
ÖAÖzgür Artunay
Özgür Artunay
ZYZeynep Yılmazabdurrahmanoğlu
Zeynep Yılmazabdurrahmanoğlu
Objectives: To evaluate the real-world outcomes of intravitreal anti-vascular endothelial growth factor (anti-VEGF) treatment in neovascular age-related macular degeneration (nAMD) patients. Materials and Methods: Multicenter, retrospective, interventional, non-comparative study. The records of nAMD patients treated with an anti-VEGF agent on a pro re nata treatment regimen basis between January 2013 and December 2015 were reviewed. The patients who completed a follow-up period of 12 months were included. Primary outcome measures of this study were the visit and injection numbers during the first year. Results: Eight hundred eighty eyes of 783 patients met the inclusion criteria for the study. Mean number of visits at month 12 was 6.9 +/- 2.5 (range: 1-15). Mean number of injections at month 12 was 4.1 +/- 1.9 (range: 1-11). Mean visual acuity at baseline and months 3, 6, and 12 was 0.90 +/- 0.63 LogMAR (range: 0.0-3.0), 0.79 +/- 0.57 LogMAR (range: 0.0-3.0), 0.76 +/- 0.57 LogMAR (range: 0.0-3.0), and 0.79 +/- 0.59 LogMAR (range: 0.0-3.0), respectively. Mean central retinal thickness at baseline and months 6 and 12 was 395 +/- 153 mu m (range: 91-1582), 330 +/- 115 mu m (range: 99-975), and 332 +/- 114 mu m (range: 106-1191), respectively. Conclusion: The numbers of visits and injections were much lower than ideal and were insufficient with the pro re nata treatment regimen.

1 October 2021 in Turkish Journal of Ophthalmology
Verified
Journal Article
Open access
APAsli Perente
Asli Perente
DKDimitra Kotsiliti
Dimitra Kotsiliti
STSergios Taliantzis
Sergios Taliantzis
Eirini Kanella PanagiotopoulouEirini Kanella Panagiotopoulou
Eirini Kanella Panagiotopoulou
MGMaria Gkika
Maria Gkika
Georgios LabirisGeorgios Labiris
Georgios Labiris
Serpiginous choroiditis (SC) is a rare, chronic, recurrent, progressive disease of unknown origin. The inflammatory process of SC can disrupt Bruch's membrane, allowing occasional choroidal vascular growth, leading to significant visual loss even in the healed stages of the disease. Optical coherence tomography angiography (OCTA) can help in the detection of choroidal neovascular membrane (CNV), leading to a definitive diagnosis and thereby guide the initiation of intravitreal anti-vascular endothelial growth factor (anti-VEGF) treatment. We report herein two cases of SC complicated with a CNV detected with OCTA and treated with a series of anti-VEGF injections.